In my opinion they did not deny them that part of the label. I wonder if it was the lawyers fighting over the exclusivity part? Or the FDA itself, trying to figure out how to handle the situation.
So is the volatility 7 million shorts or is this label just completely misunderstood?
Drug approved.... 40 million milestone payment.... will start producing and selling the drug before the other drug that has exclusivity...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.